bone formation

Balicatib (AAE581) is a potent and selective inhibitor of cathepsin K, used in trials studying the treatment of osteoporosis.

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide (Macamide Impurity 14) induces osteogenic differentiation and subsequent bone formation of mesenchymal stem cells by activating the canonical Wnt/β-catenin signaling pathway, making it useful for osteoporosis research.

CYM 50769 is a neuropeptide W/B receptor 1 (NPBWR1, GPR7) antagonist(IC50 = 0.12 μM). CYM 50769 inhibited NPW activation of NPBWR1 with a submicromolar IC50, and displayed high selectivity against a broad array of off-targets with pharmaceutical relevance.

Y1 receptor antagonist 1 FA (221697-09-2 Free base) is a highly selective neuropeptide Y1 receptor antagonist that inhibits downstream G protein-coupled signaling pathways by competitively blocking the binding of NPY to the Y1 receptor. Y1 receptor antagonist 1 FA (221697-09-2 Free base) promotes trabecular bone formation and has the potential to regulate bone mineral density (BMD) and bone formation. In animal models, Y1 receptor antagonist 1 FA (221697-09-2 Free base) reduces food intake, body weight, and fat accumulation, making it useful for obesity research.

Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It indirectly decreases osteoclast differentiation by reducing the RANKL/OPG ratio and directly increases osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways, thereby inducing bone formation via Runx2.

Sodium etidronate (Didronel) is a synthetic therapeutic diphosphonate analog of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, Sodium etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis. This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption. Etidronate may also directly stimulate bone formation by osteoblasts.

3,7,4'-Trihydroxyflavone(5-Deoxykampferol) is a DNA-breaking flavonoid isolated from rosewood heartwood. It inhibits osteoclast differentiation, actin ring formation, and bone resorption in RAW 264.7 cells and bone marrow macrophages induced by NF-κB ligand (RANKL) receptor activators.

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.

Evatanepag (CP-533536 free acid) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing.

WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.

CXM102 is an activator of autophagy. This compound induces autophagy in aged BMSCs, rejuvenating them and promoting their preferential differentiation into osteoblasts. CXM102 enhances the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. In middle-aged male mice, it stimulates bone anabolic metabolism, reduces marrow adipocytes, delays bone loss, lowers serum inflammation levels, reduces organ fibrosis, and extends lifespan.

Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.

Calcitonin-13C6,15N4 trifluoroacetic acid is a version of calcitonin (salmon) labeled with carbon-13 and nitrogen-15. This hormone regulates calcium and acts dualistically as an agonist to both amylin and calcitonin receptors, promoting bone formation while inhibiting bone resorption.

E0924G is an orally active PPARδ agonist with an EC50 of 2.82 μM. It enhances the upregulation of osteoprotegerin (OPG) expression, with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibits F-actin ring formation in RAW264.7 macrophages. Additionally, E0924G modulates bone density and bone loss in models of ovariectomy (OVX) and age-related osteoporosis.

N-Ethyl-N-nitrosourea (ENU) is a DNA alkylating agent that alkylates nucleobases and damages DNA, inducing bone marrow suppression and leukemic cell formation, leading to leukemia, tumorigenesis, genetic disorders, and teratogenicity.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

CDD-1431 is a highly selective BMPR2 kinase inhibitor with a Kiapp of 20.6 nM. It inhibits BRE reporter gene activity, exhibiting an IC50 of 4.87 μM. BMPs regulate cellular processes across various tissue types such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

LSD1-IN-32 (compound 11e) is a potent inhibitor of LSD1, with an IC50 value of 0.99 µM. It effectively impedes RANKL-induced osteoclastogenesis, bone resorption, and F-actin ring formation, indicating its potential use in osteoporosis research.

EP4 receptor antagonist 8 is an orally active EP4 receptor antagonist with an IC50 value of 6.40 nM in humans. This compound significantly reduces paw and joint swelling, infiltration of inflammatory cells, cartilage damage, pannus formation, and bone erosion in a dose-dependent manner in arthritis (AIA) mice. EP4 receptor antagonist 8 is useful for research on inflammatory pain.

E8431 is a DCSTAMP antagonist, where DCSTAMP is a crucial fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits cytoskeletal reorganization mediated by the RAP1B-RAC1 signaling pathway. It has the ability to prevent pre-osteoclast fusion, suppress bone resorption, and stimulate PDGFBB secretion, thereby promoting bone and vessel formation. E8431 effectively reduces bone loss in mouse models induced by ovariectomy. This compound can be used for osteoporosis research.

Thonzonium bromide is a mono-cationic surfactant that is structurally similar to Farnesol as an antimicrobial agent. It inhibits proton transport in a dose-dependent manner (EC50=69 μM). It inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo.

DMH2 is a selective BMP type I receptor (ALK2/ALK3) inhibitor. DMH2 inhibits the proliferation of lung cancer cell lines and induces cell death. DMH2 can be used in research on tumors, stem cell differentiation, and bone formation.